(Q30402980)

English

Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice

scientific article published on May 18, 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

1 reference

based on heuristic

inferred from title

0 references

influenza vaccine

1 reference

based on heuristic

inferred from title

mucosal immune system

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21600260

2 December 2024

8

object named as

Rebecca J Cox

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

6

object named as

Vidadi Yusibov

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Carlos Alberto Guzmán

7

object named as

Carlos A. Guzman

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21600260

2 December 2024

author name string

Jane Kristin Nøstbakken

3

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Thomas Ebensen

4

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Jessica Chichester

5

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Abdullah S. Madhun

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21600260

2 December 2024

Lars R. Haaheim

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21600260

2 December 2024

language of work or name

0 references

publication date

18 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0264410X11006499?httpAccept=text/xml

1 reference

10.1016/J.VACCINE.2011.04.094

https://api.crossref.org/works/10.1016/J.VACCINE.2011.04.094

2 December 2024

https://api.elsevier.com/content/article/PII:S0264410X11006499?httpAccept=text/plain

1 reference

10.1016/J.VACCINE.2011.04.094

https://api.crossref.org/works/10.1016/J.VACCINE.2011.04.094

2 December 2024

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

4973-4982

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Reassortment of pandemic H1N1/2009 influenza A virus in swine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

The 2009 A (H1N1) influenza virus pandemic: A review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

2009 H1N1 virus transmission and outbreaks

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Plants as alternative systems for production of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Using plant cells as influenza vaccine substrates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

The potential of 3',5'-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Th17: The ascent of a new effector T-cell subset. Preface

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Th17 cytokines in mucosal immunity and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

T-cell quality in memory and protection: implications for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Plant-expressed HA as a seasonal influenza vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Tracking the tissue distribution of marker dye following intranasal delivery in mice and chinchillas: a multifactorial analysis of parameters affecting nasal retention

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Polyfunctional T cell responses are a hallmark of HIV-2 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Induction of secretory immunity and memory at mucosal surfaces

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Mucosal immunity and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

TH1-TH2: a procrustean paradigm

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Differentiation of effector CD4 T cell populations (*)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Intranasal immunization promotes th17 immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

IL-10 production by CD4+ effector T cells: a mechanism for self-regulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Origin and homing of intestinal IgA antibody-secreting cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

based on heuristic

inferred from DOI database lookup

A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.094

7 January 2021

based on heuristic

inferred from DOI database lookup

Influenza antibody response following aerosal administration of inactivated virus

7

1 reference

10.1016/J.VACCINE.2011.04.094

https://api.crossref.org/works/10.1016/J.VACCINE.2011.04.094

2 December 2024

Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines

34

1 reference

10.1016/J.VACCINE.2011.04.094

https://api.crossref.org/works/10.1016/J.VACCINE.2011.04.094

2 December 2024

An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers

44

1 reference

10.1016/J.VACCINE.2011.04.094

https://api.crossref.org/works/10.1016/J.VACCINE.2011.04.094

2 December 2024

Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model

51

1 reference

10.1016/J.VACCINE.2011.04.094

https://api.crossref.org/works/10.1016/J.VACCINE.2011.04.094

2 December 2024

Identifiers

10.1016/J.VACCINE.2011.04.094

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30402980&oldid=2282800183"